Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma. BJS 2017; 104: 1704-1712.
Published: 26th July 2017
Authors: A. Cucchetti, V. Mazzaferro, A. D. Pinna, C. Sposito, R. Golfieri, C. Serra et al.
When comparing the efficacy of surgical and non‐surgical therapies for hepatocellular carcinoma (HCC), a major limitation is the causal inference problem. This concerns the impossibility of seeing both outcomes of two different treatments for the same individual at the same time because one is inevitably missing. This aspect can be addressed methodologically by estimating the so‐called average treatment effect (ATE).
To estimate the ATE of hepatic resection over locoregional therapies for HCC, data from patients treated in two tertiary care settings between August 2000 and December 2014 were used to obtain counterfactual outcomes using an inverse probability weight survival adjustment.
A total of 1585 patients were enrolled: 815 underwent hepatic resection, 337 radiofrequency ablation (RFA) and 433 transarterial chemoembolization (TACE). The option of operating on all patients who had tumour ablation returned an ATE of +9·8 months for resection (effect size 0·111; adjusted
ATE estimation suggests that hepatic resection is a better treatment option than ablation and TACE in patients with HCC.Read more
You may also be interested in
Survival following liver transplantation for liver‐only colorectal metastases compared with hepatocellular carcinoma.
Authors: S. Dueland, A. Foss, J. M. Solheim, M. Hagness, P.‐D. Line
Notes: Valid treatment option for colorectal liver metastases
Propensity score‐matched comparison of oncological outcomes between laparoscopic and open distal pancreatic resection.
Authors: M. Raoof, P. H. G. Ituarte, Y. Woo, S. G. Warner, G. Singh, Y. Fong et al.
Notes: No difference in survival
Authors: M. G. Keane, A. Shamali, L. N. Nilsson, A. Antila, J. Millastre Bocos, M. Marijinissen Van Zanten et al.
Notes: Low risk in small, asymptomatic mucinous cystic neoplasms
Authors: A. ten Hove, V. E. de Meijer, J. B. F. Hulscher, R. H. J. de Kleine
Notes: Choledochal cysts should be resected
Authors: M. Gelli, M. A. Allard, O. Farges, C. Paugam‐Burtz, J. Y. Mabrut, J. M. Regimbeau et al.
Notes: No increased risk
Meta‐analysis of delayed gastric emptying after pylorus‐preserving versus pylorus‐resecting pancreatoduodenectomy. BJS 2018; 105: 339-349.
Authors: U. Klaiber, P. Probst, O. Strobel, C. W. Michalski, C. Dörr‐Harim, M. K. Diener et al.
Notes: No difference
Meta‐analysis of mortality in patients with high‐risk intraductal papillary mucinous neoplasms under observation. BJS 2018; 105: 328-338.
Authors: G. Vanella, S. Crippa, L. Archibugi, P. G. Arcidiacono, G. Delle Fave, M. Falconi et al.
Notes: Low disease‐related mortality
Authors: P. Studer, T. Horn, A. Haynes, D. Candinas, V. M. Banz
Randomized clinical trial
Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. BJS 2018; 105: 192-202.
Authors: T. Ebata, S. Hirano, M. Konishi, K. Uesaka, Y. Tsuchiya, M. Ohtsuka et al.
Notes: No advantage
Defining the molecular pathology of pancreatic body and tail adenocarcinoma. BJS 2018; 105: e183-e191.
Authors: S. B. Dreyer, N. B. Jamieson, R. Upstill‐Goddard, P. J. Bailey, C. J. McKay, A. V. Biankin et al.
Notes: Worse genetic profile in tail
Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. BJS 2018; 105: e110-e120.
Authors: O. Nordgård, K. Tjensvoll, B. Gilje, K. Søreide
Notes: The inner space frontier
Authors: M. A. Stammes, S. L. Bugby, T. Porta, K. Pierzchalski, T. Devling, C. Otto et al.
Notes: Visible results